Nov 16, 2022 / 02:00PM GMT
Operator
Greetings, and welcome to Medigene corporate call. (Operator Instructions) As a reminder, this conference is being recorded. I'd now like to turn the conference over to your host, Dr. Selwyn Ho, CEO. Thank you. Please go ahead, sir.
Selwyn Ho - Medigene AG - CEO
Today, I'm delighted to share with you an update of Medigene's vision and future plans, which our team have been working on since I joined in late July of this year. Before I start, I would like to point out that I will be making forward-looking statements and point you to our disclosure here.
Medigene is an early-stage platform biotech company focused on developing differentiated, best-in-class T-cell-receptor-engineered T cell or TCR-T therapies for multiple solid tumor indications. We have a proprietary end-to-end platform for developing differentiated TCR-T therapies that consist of both product enhancement technologies, such as our PD1-41BB switch receptor, as well as development optimization technologies, such as our allogeneic-HLA or allo-HLA TCR priming tool.
Our end-to-end
Medigene AG to Discuss Updated Corporate Strategy Call Transcript
Feb 14, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers